IL143328A0 - Methods and reagents for increasing proliferative capacity and preventing replicative senescence - Google Patents

Methods and reagents for increasing proliferative capacity and preventing replicative senescence

Info

Publication number
IL143328A0
IL143328A0 IL14332899A IL14332899A IL143328A0 IL 143328 A0 IL143328 A0 IL 143328A0 IL 14332899 A IL14332899 A IL 14332899A IL 14332899 A IL14332899 A IL 14332899A IL 143328 A0 IL143328 A0 IL 143328A0
Authority
IL
Israel
Prior art keywords
reagents
methods
proliferative capacity
replicative senescence
increasing proliferative
Prior art date
Application number
IL14332899A
Original Assignee
Genetica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetica Inc filed Critical Genetica Inc
Publication of IL143328A0 publication Critical patent/IL143328A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
IL14332899A 1998-11-25 1999-11-24 Methods and reagents for increasing proliferative capacity and preventing replicative senescence IL143328A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10989198P 1998-11-25 1998-11-25
US12054999P 1999-02-17 1999-02-17
PCT/US1999/027907 WO2000031238A2 (en) 1998-11-25 1999-11-24 Methods and reagents for increasing proliferative capacity and preventing replicative senescence

Publications (1)

Publication Number Publication Date
IL143328A0 true IL143328A0 (en) 2002-04-21

Family

ID=26807479

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14332899A IL143328A0 (en) 1998-11-25 1999-11-24 Methods and reagents for increasing proliferative capacity and preventing replicative senescence

Country Status (6)

Country Link
EP (1) EP1133552A2 (en)
JP (1) JP2002530436A (en)
AU (1) AU2156600A (en)
CA (1) CA2352486A1 (en)
IL (1) IL143328A0 (en)
WO (1) WO2000031238A2 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2359244C (en) 1999-01-13 2013-10-08 Bayer Corporation .omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP1170378A1 (en) * 2000-06-26 2002-01-09 Boehringer Ingelheim International GmbH Method for monitoring the effect of cancer therapies
DE10054974A1 (en) * 2000-11-06 2002-06-06 Epigenomics Ag Diagnosis of diseases associated with Cdk4
EP1370132A2 (en) 2001-03-21 2003-12-17 Geron Corporation Use of telomerase reverse transcriptase to create homozygous knockout animals
US7262174B2 (en) 2001-05-09 2007-08-28 Geron Corporation Treatment for wounds
WO2003066839A1 (en) * 2002-02-05 2003-08-14 Rappaport Family Institute For Research In The Medical Sciences Lineage committed stem cells selected for telomerase promoter activity
JP4636486B2 (en) 2002-02-11 2011-02-23 バイエル、ファーマシューテイカルズ、コーポレイション Arylurea with angiogenesis inhibitory activity
CA2517285A1 (en) * 2003-02-26 2004-09-10 Japan Science And Technology Agency Transcriptional factor inducing apoptosis in cancer cell
ATE366108T1 (en) 2003-05-20 2007-07-15 Bayer Pharmaceuticals Corp DIARYL UREAS FOR PDGFR-MEDIATED DISEASES
EP2548880B1 (en) 2003-06-23 2019-01-09 Telomerase Activation Sciences, Inc. Compositions for increasing telomerase activity
WO2005000248A2 (en) 2003-06-25 2005-01-06 Geron Corporation Compositions and methods for skin conditioning
US8710012B2 (en) 2003-07-14 2014-04-29 Cls Therapeutics Limited Method for treating oncological diseases
US8388951B2 (en) 2003-07-14 2013-03-05 Cls Therapeutics Limited Method for treating systemic DNA mutation disease
US8431123B2 (en) 2003-07-14 2013-04-30 Cls Therapeutics Limited Method for treating systemic bacterial, fungal and protozoan infection
PL1663978T3 (en) 2003-07-23 2008-04-30 Bayer Healthcare Llc Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
WO2006035434A2 (en) * 2004-09-28 2006-04-06 Quark Biotech, Inc. Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases
EP1880733A4 (en) 2005-04-25 2009-08-12 Genkin Dmitry Dmitrievich Method for increasing longevity of a human being and animals
JP2006325444A (en) * 2005-05-24 2006-12-07 Toyobo Co Ltd Medium for cell proliferation
WO2007056423A1 (en) * 2005-11-07 2007-05-18 The General Hospital Corporation Methods and compositions for modulation of stem cell aging
ES2369547T3 (en) 2006-11-28 2011-12-01 Cls Therapeutics Limited PROCEDURE FOR THE TREATMENT OF HUMAN DISEASES ASSOCIATED WITH A HIGH CONTENT OF THE DEOXIRRIBONUCLEIC ACID IN THE EXTRACELLULAR SPACES OF THE FABRICS AND MEDICAL PREPARATION TO CARRY OUT SUCH PROCEDURE.
US8987245B2 (en) 2008-04-02 2015-03-24 Jonathan R. Brestoff Parker Composition and method for affecting obesity and related conditions
US8598150B1 (en) 2008-04-02 2013-12-03 Jonathan R. Brestoff Composition and method for affecting obesity and related conditions
EP3282021A1 (en) * 2009-03-09 2018-02-14 Bioatla, LLC Mirac proteins
CA2795981C (en) 2009-05-18 2017-06-27 Geron Corporation Compositions and methods for increasing telomerase activity
RS59462B1 (en) 2010-02-16 2019-11-29 Ultimovacs As Polypeptides
GB201202228D0 (en) * 2012-02-08 2012-03-28 Queen Mary & Westfield College Reversal of replicative senescence
US10617743B2 (en) 2014-06-19 2020-04-14 Cls Therapeutics Limited Method to improve safety and efficacy of anti-cancer therapy
ES2799515T3 (en) 2015-05-22 2020-12-18 Dmitry Dmitrievich Genkin Extracellular DNA as a therapeutic target in neurodegeneration
AU2018206485A1 (en) 2017-01-09 2019-07-11 Oisin Biotechnologies Fusogenic lipid nanoparticles and methods for manufacturing and use for therapeutic protein production and for treatment
US11905522B2 (en) 2018-01-16 2024-02-20 Cls Therapeutics Limited Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (DNase) activity
WO2019166702A1 (en) 2018-02-28 2019-09-06 Hagalife Use of a flash irradiation method to increase longevity and/or to delay the effects of ageing in mammals
US11603543B2 (en) 2018-04-18 2023-03-14 Oisin Biotechnologies, Inc. Fusogenic lipid nanoparticles for target cell-specific production of a therapeutic protein
CN113774020B (en) * 2021-08-24 2023-04-14 河北朋和生物科技有限公司 Construction method of adipose-derived mesenchymal stem cell bank

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE129407T1 (en) * 1991-10-11 1995-11-15 Squibb & Sons Inc USE OF BIPPHOSPHONATES TO PRODUCE A MEDICINAL PRODUCT FOR BLOCKING NEOPLASTIC CELL TRANSFORMATION CAUSED BY RAS ONCOGENS.
CA2118985A1 (en) * 1993-04-02 1994-10-03 Dinesh V. Patel Heterocyclic inhibitors of farnesyl protein transferase
US5721236A (en) * 1993-10-15 1998-02-24 Schering Corporation Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US6037136A (en) * 1994-10-24 2000-03-14 Cold Spring Harbor Laboratory Interactions between RaF proto-oncogenes and CDC25 phosphatases, and uses related thereto
US5624936A (en) * 1995-03-29 1997-04-29 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1998037181A2 (en) * 1997-02-20 1998-08-27 Whitehead Institute For Biomedical Research Telomerase catalytic subunit gene and encoded protein
CA2315265A1 (en) * 1998-01-12 1999-07-15 Cold Spring Harbor Laboratory Extension of cellular lifespan, methods and reagents
JP2003518359A (en) * 1998-01-30 2003-06-10 コールド スプリング ハーバー ラボラトリー Regulation of cell proliferation, methods and reagents

Also Published As

Publication number Publication date
EP1133552A2 (en) 2001-09-19
WO2000031238A2 (en) 2000-06-02
AU2156600A (en) 2000-06-13
CA2352486A1 (en) 2000-06-02
JP2002530436A (en) 2002-09-17
WO2000031238A3 (en) 2000-11-09

Similar Documents

Publication Publication Date Title
IL143328A0 (en) Methods and reagents for increasing proliferative capacity and preventing replicative senescence
EP1112028A4 (en) Cellular sublimation probe and methods
CZ20012113A3 (en) Preparations and methods for treating anorectal area
EP1102535A4 (en) Compounds and methods
SG72940A1 (en) Carrier and polishing apparatus
EP1127207A4 (en) Fold-down handle device
HUP0103473A3 (en) Phosphoglycolipid and methods for its use
AU5156999A (en) Method for determining dialysance and device for carrying out the method
IL138753A0 (en) Method and arrangement for taking up apertures
GB2368641B (en) Methods and compositions for assaying analytes
GB2336915B (en) Method and device
EP1108499A4 (en) Polishing device and polishing method
AU3562601A (en) Method for detecting and quantifying adenovirus
GB9803425D0 (en) Microtome
GB2350746B (en) Email-reception indication device and method
GB9816144D0 (en) Load handling apparatus
TW407747U (en) Securing and holding device
GB9822593D0 (en) Load handling apparatus
GB9813778D0 (en) Assay methods and means
GB2335037B (en) Sample diluter
GB9917240D0 (en) Method and means for particle measurement
GB9807112D0 (en) Sensor devices and methods for using them
GB9908469D0 (en) Cargo support device and method
GB9905827D0 (en) Document handling device
GB2375976B (en) Methods and apparatus for preventing sample loss